Erudio Healtherudio.com
Drug
Lutetium Lu 177 vipivotide tetraxetan trials: what clinicians said in public
An HCP commentary report on 1 clinical trial studying lutetium Lu 177 vipivotide tetraxetan: STARLiT. It covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 12 more trials with public commentary and no report yet.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| STARLiT NCT06574880 · Angela Y. Jia, MD PhD | locally advanced prostate cancer | Phase 1/Phase 2 | 63 | 3 | Focused | Nov 16, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| PSMAfore NCT04689828 · Novartis Pharmaceuticals DeepView → | taxane-naive metastatic castration-resistant prostate cancer | Phase 3 | Deep | View | |||
| STAMPEDE2 NCT06320067 · University College, London DeepView → | metastatic hormone-sensitive prostate cancer | Phase 3 | Deep | View | |||
| LuTectomy NCT04430192 · Peter MacCallum Cancer Centre, Australia DeepView → | high-risk localised prostate cancer | Phase 1/Phase 2 | Deep | View | |||
| PR.21 NCT04663997 · Canadian Cancer Trials Group DeepView → | PSMA-positive metastatic castration-resistant prostate cancer | Phase 2 | Deep | View | |||
| BULLSEYE NCT04443062 · Radboud University Medical Center DeepView → | oligometastatic hormone-sensitive prostate cancer | Phase 2 | Deep | View | |||
| PSMAddition NCT04720157 · Novartis Pharmaceuticals DeepView → | PSMA-positive metastatic hormone-sensitive prostate cancer | Phase 3 | Deep | View | |||
| LuCAB NCT05340374 · Peter MacCallum Cancer Centre, Australia DeepView → | metastatic castration-resistant prostate cancer | Phase 1/Phase 2 | Deep | View | |||
| UpFrontPSMA NCT04343885 · Peter MacCallum Cancer Centre, Australia FocusedView → | metastatic hormone-sensitive prostate cancer | Phase 2 | Focused | View | |||
| TheraP NCT03392428 · Australian and New Zealand Urogenital and Prostate Cancer Trials Group FocusedView → | metastatic castration-resistant prostate cancer | Phase 2 | Focused | View | |||
| VISION NCT03511664 · Endocyte FocusedView → | PSMA-positive metastatic castration-resistant prostate cancer | Phase 3 | Focused | View | |||
| LuCarbo NCT06303713 · Dana-Farber Cancer Institute FocusedView → | metastatic castration-resistant prostate cancer | Phase 1 | Focused | View | |||
| NCT03042468 NCT03042468 · Weill Medical College of Cornell University FocusedView → | Not given | Phase 1/Phase 2 | Focused | View | |||